Parallel session: NAFLD - Clinical Therapy

 Metabolism, alcohol and toxicity

Main Plenary
12 April 2019 16:00 - 18:00


PS-105 Significant regression in fibrosis in paired liver biopsies following a 12-week aerobic exercise intervention in individuals with non-alcoholic fatty liver disease
Philip O'Gorman - Ireland
12 April 2019 16:00 - 16:15

PS-106 An international, randomized, placebo-controlled phase 2 trial demonstrates novel effects of DGAT2 antisense inhibition in reducing steatosis without causing hypertriglyceridemia in T2DM patients
Rohit Loomba - United States
12 April 2019 16:15 - 16:30

PS-107 SGLT2 inhibition does not reduce hepatic steatosis in overweight, insulin resistant patients without type 2 diabetes
Thomas Marjot - United Kingdom
12 April 2019 16:30 - 16:45

PS-108 NGM313, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects
Alex DePaoli - United States
12 April 2019 16:45 - 17:00

PS-109 Partial inhibition of de novo lipogenesis with the acetyl-CoA carboxylase inhibitor PF-05221304 does not increase circulating triglycerides in humans and is sufficient to lower steatosis in rats
William Esler - United States
12 April 2019 17:00 - 17:15

PS-110 Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with nonalcoholic fatty liver disease
Roberto Calle - United States
12 April 2019 17:15 - 17:30

PS-111 Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444)
Stephen Harrison - United States
12 April 2019 17:30 - 17:45

PS-112 Endoscopic duodenal mucosal resurfacing improves hepatic fat fraction, glycemic and lipid profiles in type 2 diabetes
Guruprasad Aithal - United Kingdom
12 April 2019 17:45 - 18:00